Helen Louise Collins Sells 5,000 Shares of Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) Stock

Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA) insider Helen Louise Collins sold 5,000 shares of Bitwise MARA Option Income Strategy ETF stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total value of $219,000.00. Following the completion of the transaction, the insider owned 25,000 shares of the company’s stock, valued at approximately $1,095,000. This represents a 16.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Louise Collins also recently made the following trade(s):

• On Friday, April 17th, Helen Louise Collins sold 5,000 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $47.67, for a total value of $238,350.00.
• On Wednesday, March 25th, Helen Louise Collins sold 40,000 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $35.10, for a total value of $1,404,000.00.

Bitwise MARA Option Income Strategy ETF Stock Performance

Shares of Bitwise MARA Option Income Strategy ETF stock opened at $17.59 on Wednesday. The stock has a market cap of $3.34 million, a price-to-earnings ratio of 351.80 and a beta of 2.88. The stock has a 50 day moving average price of $16.64 and a 200-day moving average price of $15.77. Bitwise MARA Option Income Strategy ETF has a one year low of $11.99 and a one year high of $54.94.

Bitwise MARA Option Income Strategy ETF Company Profile

IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2–related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.